The CDMO is making progress with the production of different GMP batches, while a revenue growth contribution is expected to begin in the second half of 2026.
The 175,000-square-foot facility in Madison is expected to quadruple iPSC manufacturing capacity and support future contract manufacturing of cell therapy products.
The system is designed to give smaller pharmaceutical manufacturers a fast, GMP-compliant entry point into digital shop floor operations, according to the tech company.
Join this session to learn how life sciences manufacturers are leveraging advanced flow measurement insights to improve reliability, maintain compliance, and deliver confidence across every batch, cleaning cycle, and critical process.
